Effect of Tumor Necrosis Factor Inhibitors on Interstitial Lung Disease in Rheumatoid Arthritis: Angel or Demon?

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s204730
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Lung in Rheumatoid Arthritis - Focus on Interstitial Lung Disease

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

Predictors of Treatment Initiation With Tumor Necrosis Factor-Α Inhibitors in Patients With Rheumatoid Arthritis

Journal of Managed Care Pharmacy
2014English

Asymptomatic Preclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease

Clinical and Developmental Immunology
2013English

Impact of Radiological Honeycombing in Rheumatoid Arthritis-Associated Interstitial Lung Disease

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2020English

Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians

Journal of Clinical Medicine
2019English

Current Perspectives on Emerging Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease

Open Access Rheumatology: Research and Reviews
Rheumatology
2019English

Interstitial Lung Disease as an Extra-Articular Manifestation of Rheumatoid Arthritis

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2013English

OP0284 Muc5b Promoter Variant Rs35705950 Is a Risk Factor for Rheumatoid Arthritis – Interstitial Lung Disease

2018English

FRI0576 Pulmonary Ultrasound in the Assessment of Interstitial Lung Disease in Rheumatoid Arthritis

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy